Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT05447702

Recruiting

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT05390476

Recruiting

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Triple Negative Breast Cancer
NCT05305924

Recruiting

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

HER2-negative Breast Cancer | ER-Positive Breast Cancer
NCT04502680

Not yet recruiting

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (EMBRAVE-001)

Triple Negative Breast Cancer
NCT04403529

Recruiting

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT04145947

Recruiting

Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients

Triple Negative Breast Cancer
NCT04136782

Recruiting

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Breast Cancer
NCT04045522

Recruiting

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

Breast Cancer
NCT02977468

Recruiting

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Triple Negative Breast Cancer
NCT02802423

Not yet recruiting

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Triple Negative Breast Cancer
NCT05181462

Completed

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple Negative Breast Cancer
NCT04331067

Active, not recruiting

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT03756298

Active, not recruiting

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Triple Negative Breast Cancer
NCT01570998

Active, not recruiting

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Stage IA Breast Cancer | Stage IIA Breast Cancer
NCT05656131

Suspended

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
NCT05101564

Completed

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer
NCT06175390

Active, not recruiting

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE)

Triple Negative Breast Cancer
NCT07076680

Withdrawn

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Breast Cancer Metastatic | HR+/HER2- Advanced Breast Cancer
NCT04837209

Active, not recruiting

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)

Breast Cancer | Triple Negative Breast Cancer
NCT04083963

Active, not recruiting

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT01840306

Completed

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Breast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast Cancer
NCT03175666

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
NCT01815242

Completed

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

Breast Cancer
NCT04494958

Completed

Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PALBOBIN)

Triple Negative Breast Cancer
NCT02531932

Completed

Comparison of Single-Agent Carboplatin Vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Breast Cancer
NCT03487666

Completed

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Triple Negative Breast Cancer
NCT04664972

Completed

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Triple Negative Breast Cancer
NCT03387085

Terminated

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer
NCT02441933

Active, not recruiting

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Breast Cancer
NCT04997941

Active, not recruiting

Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients (MORE-T)

Hormone Receptor-positive Breast Cancer | Premenopausal Breast Cancer
NCT05112536

Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
NCT00146562

Completed

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer
NCT05809895

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer
NCT02768701

Completed

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT01765049

Active, not recruiting

Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor (DEAR)

Invasive Breast Cancer | Estrogen Receptor Positive Breast Cancer
NCT03720431

Active, not recruiting

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT02546934

Completed

ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer
NCT02499367

Active, not recruiting

Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients (TONIC)

Breast Cancer
NCT03733119

Terminated

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT05103917

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer
NCT00193050

Completed

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Breast Cancer
NCT03457779

Completed

Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT01097642

Completed

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (ICE)

Breast Cancer
NCT03872505

Withdrawn

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA)

Breast Cancer | Triple Negative Breast Cancer
NCT03186937

Terminated

A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
NCT01755130

Terminated

Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

Breast Neoplasm | Inflammatory Breast Carcinoma
NCT01150513

Completed

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Breast Cancer
NCT03244358

Terminated

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT04571437

Unknown

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) (B-001)

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer
NCT01467310

Completed

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations